Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Gilead Sciences’ long-acting drug to block HIV has the potential to end the AIDS epidemic worldwide. But accessibility ...

Everyone who wants a new HIV shot* should be given it, according to Yvette Raphael, who chaired the Global Community Advisory Group for the large-scale clinical trials of the long-acting HIV treatment ...

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

The global HIV market is expected to reach $32.1 billion by 2033, driven by long-acting injectables and innovative therapies, ...

At the Qatar Economic Forum, Elon Musk and Mishal Husain talk about the Tesla backlash, AI regulation and DOGE’s success rate ...

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from its ASCENT-03 study, leading to a significant role ...

The global response to HIV has reached a crucial juncture. Groundbreaking scientific advances, including the development of long-acting HIV prevention technologies like lenacapavir and cabotegravir, ...

One of the unique thing that we are saying is ... give lenacapavir to those who want it and who need it and who deserve it. There is usually a cascade or a priority population flow. They say ...